Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:FOLD NASDAQ:MNKD NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.75+0.6%$8.39$6.01▼$11.31$1.62B1.132.19 million shs2.22 million shsFOLDAmicus Therapeutics$8.01+3.6%$7.01$5.51▼$12.65$2.38B0.553.35 million shs7.49 million shsMNKDMannKind$5.37-0.2%$4.26$3.38▼$7.63$1.65B1.025.69 million shs3.12 million shsRIGLRigel Pharmaceuticals$34.98-6.2%$30.85$13.37▼$43.72$669.06M1.27710,343 shs405,666 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-2.65%-5.98%-8.00%-22.77%-2.78%FOLDAmicus Therapeutics-3.25%-3.13%+4.46%+33.28%-31.59%MNKDMannKind-3.41%-3.41%+44.24%+43.47%-14.19%RIGLRigel Pharmaceuticals-1.74%-8.74%-5.59%+94.68%+172.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.75+0.6%$8.39$6.01▼$11.31$1.62B1.132.19 million shs2.22 million shsFOLDAmicus Therapeutics$8.01+3.6%$7.01$5.51▼$12.65$2.38B0.553.35 million shs7.49 million shsMNKDMannKind$5.37-0.2%$4.26$3.38▼$7.63$1.65B1.025.69 million shs3.12 million shsRIGLRigel Pharmaceuticals$34.98-6.2%$30.85$13.37▼$43.72$669.06M1.27710,343 shs405,666 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-2.65%-5.98%-8.00%-22.77%-2.78%FOLDAmicus Therapeutics-3.25%-3.13%+4.46%+33.28%-31.59%MNKDMannKind-3.41%-3.41%+44.24%+43.47%-14.19%RIGLRigel Pharmaceuticals-1.74%-8.74%-5.59%+94.68%+172.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.70115.48% UpsideFOLDAmicus Therapeutics 2.78Moderate Buy$16.0099.75% UpsideMNKDMannKind 3.17Buy$11.17107.95% UpsideRIGLRigel Pharmaceuticals 2.40Hold$38.209.21% UpsideCurrent Analyst Ratings BreakdownLatest RIGL, FOLD, BCRX, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/2/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.008/26/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.008/25/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/7/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.008/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $32.008/4/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.007/23/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$10.00 ➝ $8.007/17/2025FOLDAmicus TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight7/16/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$9.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M3.61N/AN/A($2.30) per share-3.37FOLDAmicus Therapeutics$528.29M4.67N/AN/A$0.65 per share12.32MNKDMannKind$285.50M5.77$0.14 per share38.77($0.29) per share-18.52RIGLRigel Pharmaceuticals$179.28M3.50$1.01 per share34.57$0.19 per share184.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/A1.55-6.41%N/A-1.78%11/3/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.12N/A18.63N/A-6.67%-5.07%-1.23%11/5/2025 (Estimated)MNKDMannKind$27.59M$0.1148.8223.35N/A10.87%-32.60%7.81%11/6/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$5.416.4733.31N/A36.51%438.89%57.03%11/6/2025 (Estimated)Latest RIGL, FOLD, BCRX, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 million8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.252.22FOLDAmicus Therapeutics1.923.212.29MNKDMannKindN/A2.502.24RIGLRigel Pharmaceuticals0.462.021.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%FOLDAmicus TherapeuticsN/AMNKDMannKind49.55%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals5.10%FOLDAmicus Therapeutics2.20%MNKDMannKind3.00%RIGLRigel Pharmaceuticals9.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableFOLDAmicus Therapeutics480308.24 million301.46 millionOptionableMNKDMannKind400306.83 million297.62 millionOptionableRIGLRigel Pharmaceuticals16017.94 million16.32 millionOptionableRIGL, FOLD, BCRX, and MNKD HeadlinesRecent News About These CompaniesAcadian Asset Management LLC Grows Stock Position in Rigel Pharmaceuticals, Inc. $RIGLSeptember 15 at 4:37 AM | marketbeat.comDynamic Technology Lab Private Ltd Acquires Shares of 27,117 Rigel Pharmaceuticals, Inc. $RIGLSeptember 13 at 3:58 AM | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Shares Down 6.1% - Here's What HappenedSeptember 11, 2025 | marketbeat.comCan Tavalisse Drive Rigel's Growth Through the Rest of 2025?September 11, 2025 | zacks.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Drop in Short InterestSeptember 11, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Grows Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 11, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Recommendation of "Hold" by AnalystsSeptember 11, 2025 | marketbeat.comWhat Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comA Look At The Intrinsic Value Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)September 9, 2025 | uk.finance.yahoo.comTrexquant Investment LP Lowers Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 9, 2025 | marketbeat.comDo Options Traders Know Something About RIGL Stock We Don't?September 6, 2025 | msn.comRafferty Asset Management LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGLSeptember 5, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 11,070 Shares of Rigel Pharmaceuticals, Inc. $RIGLSeptember 3, 2025 | marketbeat.comArmistice Capital LLC Has $27.27 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 2, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. $RIGL Shares Bought by Wellington Management Group LLPSeptember 2, 2025 | marketbeat.com115,218 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Nuveen LLCSeptember 1, 2025 | marketbeat.comInvesco Ltd. Purchases Shares of 134,072 Rigel Pharmaceuticals, Inc. $RIGLSeptember 1, 2025 | marketbeat.comVanguard Group Inc. Has $18.50 Million Stake in Rigel Pharmaceuticals, Inc. $RIGLSeptember 1, 2025 | marketbeat.comRigel to Participate in Upcoming September Investor ConferencesAugust 26, 2025 | prnewswire.comThis ‘Darling’ Pharma Stock Is Hitting New Highs, But the Momentum Could Run Out SoonAugust 25, 2025 | finance.yahoo.comThis ‘Darling’ Pharma Stock Is Hitting New HighsAugust 25, 2025 | barchart.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRIGL, FOLD, BCRX, and MNKD Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$7.75 +0.05 (+0.65%) Closing price 04:00 PM EasternExtended Trading$7.77 +0.02 (+0.26%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Amicus Therapeutics NASDAQ:FOLD$8.01 +0.28 (+3.62%) Closing price 04:00 PM EasternExtended Trading$7.92 -0.09 (-1.06%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.MannKind NASDAQ:MNKD$5.37 -0.01 (-0.19%) Closing price 04:00 PM EasternExtended Trading$5.38 +0.01 (+0.11%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Rigel Pharmaceuticals NASDAQ:RIGL$34.98 -2.32 (-6.22%) Closing price 04:00 PM EasternExtended Trading$34.99 +0.02 (+0.04%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
